Jupiter Life Lin

Why is Jupiter Life Line Hospitals Ltd falling/rising?

As of 22-Jun, Jupiter Life Line Hospitals Ltd is seeing a slight stock price increase to 1,357.35, driven by heightened investor interest and a 2.46% gain over the past week. However, its long-term performance remains weak, with a -6.53% return over the past year and underperformance against its sector, indicating caution for investors.

As of 22-Jun, Jupiter Life Line Hospitals Ltd is experiencing a slight rise in its stock price, currently at 1,357.35, reflecting an increase of 15.1 points or 1.12%. This upward movement can be attributed to several factors. Notably, the stock has shown a positive performance over the past week, gaining 2.46%, which outpaces the Sensex's increase of 1.09% during the same period. Additionally, there has been a significant rise in investor participation, with delivery volume increasing by 139.44% compared to the 5-day average, indicating heightened interest in the stock.<BR><BR>Despite these positive indicators, the stock has underperformed its sector by 0.32% today and has a mixed long-term outlook. It has generated a return of -6.53% over the past year, which is slightly worse than the BSE500 index. Furthermore, while the company's profits have risen by 2.2% over the past year, the overall performance remains below par in both the near and long term. The stock is trading at a premium compared to its peers, and despite high institutional holdings at 25.49%, which typically suggests confidence in the stock, the company has shown poor long-term growth with an operating profit growth rate of only 16.24% over the last five years.<BR><BR>In summary, while Jupiter Life Line Hospitals Ltd is currently rising in price due to increased investor interest and short-term gains, its long-term performance and recent underperformance against benchmarks suggest caution for investors.

Which are the latest news on Jupiter Life Lin?

What does Jupiter Life Lin do?

Jupiter Life Line Hospitals Ltd, a small-cap company established in 2002 in Mumbai, operates in the hospital industry, reporting net sales of 388 Cr and a net profit of 50 Cr for March 2026. Key metrics include a P/E of 43.00 and a market cap of INR 8,744 Cr.

Overview: <BR>Jupiter Life Line Hospitals Ltd operates in the hospital industry and is categorized as a small-cap company.<BR><BR>History: <BR>Jupiter Life Line Hospitals Limited was incorporated in 2002 in Mumbai, Maharashtra, and commenced its business operations in December of the same year. The latest quarterly results reported net sales and net profit for March 2026.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 388 Cr (Quarterly Results - Mar 2026) <BR>Most recent Net Profit: 50 Cr (Quarterly Results - Mar 2026) <BR>Market-cap value: INR 8,744 Cr (Small Cap)<BR><BR>Key Metrics: <BR>P/E: 43.00 <BR>Industry P/E: 60 <BR>Dividend Yield: 0.15% <BR>Debt-Equity: 0.03 <BR>Return on Equity: 12.80% <BR>Price to Book: 5.67 <BR><BR>Contact Details: <BR>No Company Details Available <BR>Registrar Address: Not available.

How big is Jupiter Life Lin?

As of 10th June, Jupiter Life Line Hospitals Ltd has a market capitalization of 8,744.00 Cr, with recent net sales of 1,499.79 Cr and a net profit of 194.00 Cr over the last four quarters.

As of 10th June, <BR><BR>Market Cap: Jupiter Life Line Hospitals Ltd has a market capitalization of 8,744.00 Cr, categorizing it as a Small Cap company.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters is 1,499.79 Cr, while the sum of Net Profit for the same period stands at 194.00 Cr.<BR><BR>Balance Sheet Snapshot: The reporting period for the balance sheet is March 2025. Shareholder's Funds are valued at 1,356.24 Cr, and Total Assets amount to 1,904.89 Cr.

Who are in the management team of Jupiter Life Lin?

The management team of Jupiter Life Lin includes Ajay Pratap Thakker (Chairman & Managing Director), Ankit Ajay Thakker (Executive Director & CEO), and several non-executive and independent directors, along with Suma Upparatti as Company Secretary & Compliance Officer, overseeing the company's strategic direction and governance.

The management team of Jupiter Life Lin includes the following key members:<BR><BR>1. **Ajay Pratap Thakker** - Chairman & Managing Director<BR>2. **Ankit Ajay Thakker** - Executive Director & CEO<BR>3. **Bhaskar Prataprai Shah** - Non-Executive Director<BR>4. **Vadapatra Sayee Raghavan** - Non-Executive Director<BR>5. **Darshan Hiralal Vora** - Independent Director<BR>6. **Jasmin A Patel** - Independent Director<BR>7. **Urmi Popat** - Independent Director<BR>8. **Satish Utekar** - Independent Director<BR>9. **Suma Upparatti** - Company Secretary & Compliance Officer<BR><BR>This team is responsible for the strategic direction and governance of the company.

Who are the peers of the Jupiter Life Lin?

Jupiter Life Lin's peers include Krishna Institute, Dr. Agarwal's Health, Rainbow Children's Hospital, Health.Global, Yatharth Hospital, Jeena Sikho, Kovai Medical Center, Artemis Medicare, and Indraprastha Medical. Jupiter Life Lin has below-average growth and a 1-year return of -13.75%, underperforming compared to its peers.

Peers: The peers of Jupiter Life Lin are Krishna Institu., Dr Agarwal's Hea, Rainbow Child., Health.Global, Yatharth Hospit., Jeena Sikho, Kovai Medical, Artemis Medicare, and Indrapr.Medical.<BR><BR>Quality Snapshot: Excellent management risk is observed at Krishna Institu., Rainbow Child., Kovai Medical, and Jeena Sikho, while Average management risk is found at Dr Agarwal's Hea, Health.Global, Yatharth Hospit., Artemis Medicare, and Indrapr.Medical. Below Average management risk is noted at Yatharth Hospit. Regarding growth, Excellent growth is seen at Health.Global and Jeena Sikho, while Good growth is found at Dr Agarwal's Hea, Yatharth Hospit., and Artemis Medicare. Below Average growth is present at Krishna Institu., Rainbow Child., and Jupiter Life Lin, while Average growth is noted at Kovai Medical. Jupiter Life Lin has an Excellent capital structure, alongside Indrapr.Medical and Jeena Sikho, while Good capital structure is observed at Krishna Institu., Dr Agarwal's Hea, Rainbow Child., Kovai Medical, and Artemis Medicare.<BR><BR>Return Snapshot: Yatharth Hospit. has the highest 1-year return at 57.94%, while Jeena Sikho has the lowest return, which is not available. Jupiter Life Lin's 1-year return is -13.75%, indicating a significant underperformance compared to its peers. Additionally, Health.Global, Jupiter Life Lin, Jeena Sikho, Indrapr.Medical, and Dr Agarwal's Hea have negative six-month returns.

Should I buy, sell or hold Jupiter Life Line Hospitals Ltd?

Are Jupiter Life Line Hospitals Ltd latest results good or bad?

Jupiter Life Line Hospitals Ltd's latest results show a 15.20% increase in net sales and an 18.00% rise in net profit, indicating positive revenue growth. However, declining operating margins and rising interest costs raise concerns about profitability and financial sustainability.

Jupiter Life Line Hospitals Ltd's latest results present a mixed picture. On the positive side, the company reported a 15.20% year-on-year increase in net sales, reaching ₹387.84 crores, and a sequential growth of 6.15%. Additionally, the consolidated net profit for the quarter rose by 18.00% compared to the previous quarter, totaling ₹50.21 crores.<BR><BR>However, there are notable concerns regarding profitability. The operating margin, excluding other income, contracted to 22.99% from 23.67% in the same quarter last year, indicating pressure on profitability despite the revenue growth. Furthermore, interest costs surged to ₹9.01 crores, the highest quarterly level recorded, which raises concerns about the sustainability of profit margins moving forward.<BR><BR>Overall, while the revenue growth is encouraging, the declining profitability margins and rising interest expenses suggest that the company's financial health is under pressure. Investors should weigh these factors carefully when assessing the company's performance.

When is the next results date for Jupiter Life Line Hospitals Ltd?

The next results date for Jupiter Life Line Hospitals Ltd is 15 May 2026.

The next results date for Jupiter Life Line Hospitals Ltd is scheduled for 15 May 2026.

Is Jupiter Life Lin technically bullish or bearish?

As of November 14, 2025, the trend is mildly bullish due to a bullish MACD and moving averages, but mixed signals from Bollinger Bands and RSI suggest caution.

As of 14 November 2025, the technical trend has changed from bullish to mildly bullish. The current stance is mildly bullish, driven by a bullish MACD on the weekly timeframe and mildly bullish moving averages on the daily timeframe. However, the weekly Bollinger Bands indicate a bearish sentiment, and the RSI shows no signals on both weekly and monthly timeframes. The Dow Theory reflects a mildly bullish position on the weekly chart, while the monthly shows no trend. Overall, the strength of the bullish stance is tempered by mixed signals from other indicators.

How has been the historical performance of Jupiter Life Lin?

Jupiter Life Lin experienced significant growth from March 2023 to March 2025, with net sales rising from 892.54 Cr to 1,302.40 Cr and profit after tax increasing from 72.91 Cr to 193.75 Cr, alongside a substantial rise in total assets. Overall, the company demonstrated robust improvements in sales, profitability, and asset base during this period.

Answer:<BR>The historical performance of Jupiter Life Lin shows significant growth across various financial metrics from March 2023 to March 2025.<BR><BR>Breakdown:<BR>Jupiter Life Lin's net sales increased from 892.54 Cr in March 2023 to 1,302.40 Cr in March 2025, reflecting a strong upward trend. The total operating income followed a similar trajectory, rising from 892.54 Cr to 1,302.40 Cr over the same period. Total expenditure, excluding depreciation, also grew from 691.22 Cr to 1,002.29 Cr, indicating increased operational costs. Operating profit (PBDIT) saw a notable increase from 211.74 Cr in March 2023 to 328.46 Cr in March 2025, with the operating profit margin slightly improving to 23.04% in March 2025. Profit before tax rose from 128.71 Cr to 260.68 Cr, while profit after tax increased from 72.91 Cr to 193.75 Cr, showcasing enhanced profitability. The consolidated net profit also grew from 72.91 Cr to 193.20 Cr. On the balance sheet, total assets surged from 985.53 Cr in March 2023 to 1,904.89 Cr in March 2025, with total liabilities increasing from 985.53 Cr to 1,904.89 Cr. Cash flow from operating activities remained stable, with a net cash inflow of 166.00 Cr in March 2024, up from 31.00 Cr in March 2023. Overall, Jupiter Life Lin demonstrated robust growth in sales, profits, and asset base over the observed period.

How has been the historical performance of Jupiter Life Lin?

Jupiter Life Lin has demonstrated significant growth over the past three years, with net sales increasing from 892.54 Cr to 1,302.40 Cr, and profit after tax rising from 72.91 Cr to 193.75 Cr. Key financial metrics, including operating profit and earnings per share, also showed substantial improvement during this period.

Answer:<BR>The historical performance of Jupiter Life Lin shows significant growth across various financial metrics over the past three years.<BR><BR>Breakdown:<BR>Jupiter Life Lin's net sales have increased from 892.54 Cr in March 2023 to 1,302.40 Cr in March 2025, reflecting a strong upward trend. The total operating income followed a similar trajectory, rising from 892.54 Cr to 1,302.40 Cr during the same period. Total expenditure, excluding depreciation, also grew from 691.22 Cr to 1,002.29 Cr, indicating increased operational costs. Operating profit (PBDIT) rose from 211.74 Cr in March 2023 to 328.46 Cr in March 2025, while profit before tax improved from 128.71 Cr to 260.68 Cr. The profit after tax also saw a notable increase, growing from 72.91 Cr to 193.75 Cr. The earnings per share (EPS) increased significantly from 12.9 to 29.46, demonstrating enhanced profitability per share. On the balance sheet, total assets expanded from 985.53 Cr in March 2023 to 1,904.89 Cr in March 2025, with total liabilities also rising from 985.53 Cr to 1,904.89 Cr. Cash flow from operating activities remained relatively stable, while net cash inflow surged from 31 Cr in March 2023 to 166 Cr in March 2024, indicating improved liquidity. Overall, Jupiter Life Lin has shown robust growth in sales, profits, and asset base over the past three years.

Who are the top shareholders of the Jupiter Life Lin?

The top shareholders of Jupiter Life Lin include promoters, with Ajay P Thakker holding 20.74%, and institutional investors, including mutual funds at 11.09% and foreign institutional investors at 10.03%. Individual investors collectively own 24.54%, with SBI Healthcare Opportunities Fund as the largest public shareholder at 7.29%.

The top shareholders of Jupiter Life Lin include a mix of promoters, institutional investors, and individual shareholders. The majority shareholders are the promoters, with Ajay P Thakker holding the highest individual stake at 20.74%. <BR><BR>In terms of institutional holdings, mutual funds collectively hold 11.09% through 15 different schemes, while foreign institutional investors (FIIs) account for 10.03% with 75 different FIIs involved. The highest public shareholder is the SBI Healthcare Opportunities Fund, which holds 7.29%. Additionally, individual investors collectively hold 24.54% of the company's shares.

Is Jupiter Life Lin overvalued or undervalued?

As of June 11, 2025, Jupiter Life Lin is considered overvalued with a valuation grade of expensive, reflected in its high PE ratio of 51.71 and premium compared to peers, despite a strong 24.33% return over the past year.

As of 11 June 2025, Jupiter Life Lin's valuation grade has moved from very expensive to expensive, indicating a slight improvement in its valuation outlook. The company is currently considered overvalued. Key financial ratios include a PE ratio of 51.71, an EV to EBITDA of 33.35, and a Price to Book Value of 7.37, all of which suggest a high valuation relative to its earnings and book value.<BR><BR>In comparison to its peers, Jupiter Life Lin's PE ratio is significantly higher than that of Narayana Hrudaya at 47.19 and Apollo Hospitals at 68.89, both of which are also in the expensive category. This indicates that Jupiter Life Lin is trading at a premium compared to its peers, which raises concerns about its valuation. Additionally, while the stock has outperformed the Sensex over the past year with a return of 24.33% compared to the Sensex's 7.92%, the overall high valuation metrics suggest that investors should exercise caution.

Has Jupiter Life Lin declared dividend?

Jupiter Life Line Hospitals Ltd has declared a 10% dividend, amounting to ₹1 per share, with an ex-date of August 2, 2024. While the 1-year total return is 25.66%, the 6-month return is -5.44%, and there have been no returns over longer periods.

Jupiter Life Line Hospitals Ltd has declared a 10% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 10%<BR>- Amount per share: 1 per share<BR>- Ex-date: 02 Aug 24<BR><BR>Dividend Yield: 0.07%.<BR><BR>Total Returns by Period:<BR>In the 6-month period, the price return was -5.44%, the dividend return was 0%, resulting in a total return of -5.44%.<BR><BR>For the 1-year period, the price return was 25.58%, the dividend return was 0.08%, leading to a total return of 25.66%.<BR><BR>Over the 2-year period, there was no price return or dividend return, resulting in a total return of 0.0%.<BR><BR>In the 3-year period, there were no price or dividend returns, leading to a total return of 0.0%.<BR><BR>For the 4-year period, there were again no price or dividend returns, resulting in a total return of 0.0%.<BR><BR>In the 5-year period, there were no price or dividend returns, leading to a total return of 0.0%.<BR><BR>Overall, while Jupiter Life Line Hospitals Ltd has declared a dividend, the total returns over various periods show mixed results, with significant returns in the 1-year period but negative returns in the 6-month period. The lack of returns in longer periods indicates potential volatility or stagnation in performance.